ISHL International Symposium on Hodgkin Lymphoma Program at a Glance

Saturday (26.10.2024) Sunday (27.10.2024) Monday (28.10.2024)
 
Großer Saal


Pediatric and Adolescent Treatment Concepts

  • J. Friedberg
  • C. Mauz-Körholz

  1. Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective

    • S. Castellino

  2. Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective

    • C. Mauz-Körholz

  3. Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization

    • J. Flerlage

  4. Oral presentation of selected abstracts
Großer Saal


Special Situations & Cases

  • A. Fosså
  • A. Sureda

  1. Treatment Approaches in Ressource Constraint Settings

    • C. Asirwa
    • O. Baiocchi

  2. HL Richter Transformation Pathologists perspective

    • S. Hartmann

  3. HL Richter Transformation HL perspective

    • M. Hertzberg

  4. HL Richter Transformation CLL perspective

    • O. Al-Sawaf
Marsilius Saal


Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma (Separate registration required)

  • S. Barrington
  • S. Borchmann
  • C. Kobe
  • W. Plattel
  • D. Rossi
Großer Saal


EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas”

  • I. Aurer
  • B. von Tresckow

  1. Introduction

  2. Molecular and microenvironmental vulnerabilities of B-cell lymphomas

    • S. Leppä

  3. Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?

    • M. Kersten

  4. Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?

    • C. Thieblemont

  5. How to implement novel ADCs in the first-line treatment of lymphoma

    • P. Zinzani

  6. Perspectives of small molecule based first-line therapy of LBCL

    • T. Vasilakopoulos

  7. Treatment and Trial Landscape for Malignant Lymphoma in China

    • Y. Song
Coffee Break
Großer Saal


NLPHL

  • R. Hoppe
  • W. Klapper

  1. NLPHL: HL, NHL or something else?

    • S. Hartmann

  2. First-line treatment of NLPHL with HL-directed approaches

    • D. Eichenauer

  3. Treatment of NLPHL with NHL-directed approaches

    • G. Collins
Coffee Break
Großer Saal


Biology & Microenvironment

  • S. Leppä
  • M. Shipp

  1. Pathogenesis of HL

    • R. Küppers

  2. Multimodal characterization of cHL

    • C. Steidl

  3. Oral presentation of selected abstracts
Coffee Break
Großer Saal


Living Beyond Lymphoma

  • J. Radford
  • F. van Leeuwen

  1. Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)

    • S. Ansell

  2. Starting Living beyond Lymphoma with HL diagnosis

    • K. Behringer

  3. Participation in and (cost-)effectiveness of the Dutch HL survivorship care program

    • B. Aleman
    • A. Nijdam

  4. Oral presentation of selected abstracts
Coffee Break
Großer Saal


Limited Stages

  • M. André
  • L. Specht

  1. IIntro: Treatment concepts in early-stage HL

    • M. André

  2. Viewpoint: Systemic Therapy only in the future?

    • R. Advani

  3. Viewpoint: CMT (is it there to stay?)

    • J. Yahalom

  4. Oral presentation of selected abstracts
Coffee Break
Großer Saal


Satellite Symposium 2

by MSD
  • P. Borchmann

  1. B-cell lymphoma pathology – illustrated for non- pathologists

    • W. Klapper

  2. Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

    • P. Borchmann

  3. Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

    • S. Dietrich
Coffee Break
Großer Saal


Relapsed & Refractory HL

  • P. Armand
  • C. Moskowitz

  1. Updated approach to second-line treatment

    • A. Moskowitz

  2. Emerging strategies to overcome anti-PD1 resistance

    • S. Ansell

  3. Implementing raditoherapeutic concepts in rrHL care

    • C. Baues

  4. Oral presentation of selected abstracts
 
Großer Saal


Satellite Symposium 1

by Beigene
  • C. Buske

  1. Welcome and Introduction

    • C. Buske

  2. BTKis in indolent lymphomas (FL, MZL)

    • C. Thieblemont

  3. BTKis in WM

    • C. Buske

  4. BTKis in MCL

    • D. Lewis

  5. Future developments (CDAC, BCL2, anti PD1/PDL1)

    • A. Frustaci

  6. Panel discussion, audience Q&A

  7. Closure and farewell

    • C. Buske
Coffee Break
Großer Saal


Older Patients

  • P. Bröckelmann
  • A. Evens

  1. Implementing Frailty Assessment for Treatment Guidance in HL

    • S. Rutherford

  2. Optimal Use of Targeted Agents to Address Unmet Need in Older HL

    • G. Collins

  3. Oral presentation of selected abstracts
Großer Saal


Closing remarks

  • R. Advani
  • S. Barrington
  • S. Borchmann
  • C. Kobe
  • W. Plattel

  1. Workshop Report

    • S. Barrington
    • S. Borchmann
    • C. Kobe
    • W. Plattel
    • D. Rossi

  2. Best of ISHL13

    • R. Advani

  3. Farewell

    • P. Borchmann
Coffee Break
Großer Saal


Opening and Award Ceremony

  1. Welcome Address

    • P. Borchmann
    • V. Diehl

  2. Award Ceremony

    • P. Borchmann
    • S. Borchmann
    • P. Bröckelmann
    • D. Eichenauer

  3. Keynote Lecture

    • L. Partridge
Coffee Break
Großer Saal


Satellite Symposium 3

by Takeda
  • P. Borchmann
Coffee Break
Foyer (First Floor)


Poster Session & Welcome Reception

  1. All poster presenters are required to be present at their poster boards from 17:15 to 19:00
Coffee Break
Großer Saal


Advanced Stages

  • A. Herrera
  • J. Zijlstra

  1. Individualized treatment de-escalation improves overall outcomes

    • P. Borchmann

  2. Immune-chemotherapy overcomes the need for individualization

    • J. Friedberg

  3. Oral presentation of selected abstracts
 
 
  •   Educational
  •   Main Program
  •   Satellite Symposium
  •   Scientific Session
  •   Seminar/Workshop